Active vitamin D has been used for nearly 50 years and is widely applied in various countries around the world for the treatment of orthopedic diseases, endocrine diseases, skin conditions, and other therapeutic areas. It has demonstrated positive and reliable efficacy and safety in multiple clinical studies both domestically and internationally. In recent years, there has been a continuous surge in research and development related to vitamin D receptors (VDR) targeted by active vitamin D. Multiple molecular studies and animal experiments have confirmed that active vitamin D has great potential for development in the treatment of tumors, rare diseases, cardiovascular diseases, and other areas.
Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') officially released the 'Current Status and Future Development Report of the Active Vitamin D (Calcitriol) Industry' (hereinafter referred to as the 'Report') on January 29, 2024. The report conducts an in-depth analysis of the active vitamin D field, systematically elaborating on multiple dimensions such as technological development, application areas, market status, clinical progress, industry challenges, corporate competitive landscape, and future trends. It tracks the development context of the industry and technology, explores industry growth potential, reveals the driving factors behind market development, and looks ahead to the broad market prospects of active vitamin D.
